Aktienanalyse zu Tevogen Bio Holdings Inc (TVGN)TVGNTevogen Bio Holdings Inc

Tevogen Inc., formerly Tevogen Bio Holdings Inc., is a socially integrated healthcare enterprise. The Company leverages artificial intelligence and precision T cell therapy platforms, and engagements with global technology companies to support the development of advanced, life-saving therapies across multiple therapeutic areas and scalable solutions for the broader healthcare system. Tevogen Bio, its lead initiative, has completed a proof-of-concept clinical trial demonstrating the potential of its single-HLA-restricted, genetically unmodified allogeneic T cells. Tevogen Bio's pipeline spans virology, oncology, and neurology. Tevogen.AI is designed to transform drug development by accelerating target detection, helping reduce failure rates, and supporting optimized clinical trial design through proprietary predictive technologies. It is exploring strategic initiatives that may include domestic generics, biosimilars, medical devices, and insurance solutions for healthcare providers. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES industry).

Tevogen Bio Holdings Inc. is not a good buy right now. The current price is $5.59, which is significantly down 69.27% year-to-date and 80.99% over the past year. The RSI is at a very low 20.26, indicating oversold conditions but also reflecting persistent bearish sentiment. The company has reported negative net income for multiple quarters, with the latest net income at -$5,839,776 for Q2 2026. The main risk is the company's ongoing financial losses and a current ratio of only 0.33, suggesting liquidity issues. Without a clear path to profitability or positive catalysts, it is advisable to avoid this stock for now.